Zavabresib

Zavabresib
Clinical data
Other names	OPN-2853; PLX-2853; PLX124-01
Identifiers
	IUPAC name 4-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(1,1-dipyridin-2-ylethyl)pyrrolo[3,2-b]pyridin-3-yl]benzoic acid;
CAS Number	2089390-09-8;
PubChem CID	126689208;
ChemSpider	129953265;
UNII	WY57S8PGY9;
Chemical and physical data
Formula	C31H25N5O3
Molar mass	515.573 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=NO1)C)C2=CC3=C(C(=CN3C(C)(C4=CC=CC=N4)C5=CC=CC=N5)C6=CC=C(C=C6)C(=O)O)N=C2;
	InChI InChI=InChI=1S/C31H25N5O3/c1-19-28(20(2)39-35-19)23-16-25-29(34-17-23)24(21-10-12-22(13-11-21)30(37)38)18-36(25)31(3,26-8-4-6-14-32-26)27-9-5-7-15-33-27/h4-18H,1-3H3,(H,37,38); Key:LLUTURRCWNCHPC-UHFFFAOYSA-N;

Zavabresib is an investigational new drug that is being evaluated by Plexxikon/Opna Bio for the treatment of myelofibrosis. It is a BRD4 protein inhibitor.^[1]^[2]

References

↑ "Zavabresib - Opna Bio". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ Gordon MS, Carvajal RD, Spira A, Huang M, Inokuchi K, Chen PY, et al. (March 2026). "BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial". Cancer Chemotherapy and Pharmacology. 96 (1) 20. doi:10.1007/s00280-026-04871-3. PMID 41787121.